December 18, 2018 08:46 AM EST

Novartis CAR-T chief drops out of Big Pharma, joins the great migration to a favorite biotech destination

John Carroll

Editor & Founder

Novartis may still have big plans for CAR-T, but the pharma giant continues to bleed top talent from the group.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER

Novartis CAR-T chief drops out of Big Pharma, joins the great migration to a favorite biotech destination

John Carroll

Editor & Founder

Unlock this article instantly by becoming a free subscriber.

Associate Director, Market Insights and Analytics

Celldex Therapeutics

Hampton, NJ, USA

Lilly scraps trials of Verzenio, Jardiance and a gene therapy from Prevail

Updated: Lilly boosts sales guidance by $2B, but GLP-1 supply constraints still a focus

Real Chemistry debuts a one-stop dashboard for all things GLP-1

FTC targets more drug patents, going after obesity, diabetes and asthma medications

In one of JP Morgan's first biotech bets, Enlaza raises $100M for its permanently binding protein drugs

A New Precision Approach for Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

No­var­tis CAR-T chief drops out of Big Phar­ma, joins the great mi­gra­tion to a fa­vorite biotech des­ti­na­tion

Editor & Founder

Unlock this article instantly by becoming a free subscriber.

Celldex Therapeutics

Hampton, NJ, USA

Novartis CAR-T chief drops out of Big Pharma, joins the great migration to a favorite biotech destination